An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice

Inclusion Criteria

• •A diagnosis of ulcerative colitis (UC), with signs and symptoms consistent with UC for at least 3 months prior to the first study intervention administration
• •Moderate to severely active UC disease activity, defined as a modified Mayo score of 4 through 9, inclusive, with the following minimum subscores:
• •i) An SF subscore ≥ 1, AND ii) An RB subscore ≥ 1, AND iii) An ES ≥ 2 (endoscopy performed within 60 days of the first study intervention administration).
• •Report of a previous colonoscopy that documents extent of disease